Theranostic Applications of Radionuclides in Prostate Cancer
Recruiting · NCT07559201 · Interventional (participants receive a specific treatment) · Lead sponsor: Guilin Medical University, China
View the official record on ClinicalTrials.gov →Interventions studied
standard-of-care imaging (PSMA/FDG PET/CT), ACP3 PET/CT
What this trial is about
The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Adult patients (aged 18 years or older);
- Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);
- Patients who had scheduled both standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT scans;
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion criteria
- The inability or unwillingness of the research participant or legal representative to provide written informed consent.
Where it is running
1 location listed.
- The First Affliated Hospital of Guilin Medical University - Guilin, Guangxi, China